Biosimilars

Anti-TNF Therapies

Our portfolio of anti-TNF therapies is marketed in the European Union. TNF inhibitors are a type of therapy to treat inflammatory conditions, such as rheumatoid arthritis (RA), psoriatic arthritis, juvenile arthritis, inflammatory bowel disease (Crohn’s and ulcerative colitis), ankylosing spondylitis, and psoriasis. They reduce inflammation and stop disease progression by targeting an inflammation-causing substance called Tumor Necrosis Factor (TNF).

 

Anti-VEGF Therapies

Our portfolio is expanding to include anti-VEGF (vascular endothelial growth factor) therapies, which will be marketed in the European Union, as well as other major markets worldwide, including the U.S., Canada, Japan and Australia. Anti-VEGF therapies treat retinal vascular disorders, which are a leading cause of blindness.

These therapies are biosimilars, referencing originator products already available. We are excited about the potential to bring biosimilars to a new therapeutic area and expand our biosimilar offering with the goal of sustainably advancing broad access to care for patients in need.

By bridging our heritage of scientific innovation with an opportunity to reduce healthcare costs and increase access to biologics, developing biosimilars is a compelling way in which we can make a difference in the lives of the patients we serve.

Biosimilars

Biosimilars are a classification of biologic medicines that are similar to currently available biologic therapies known as originators. Having successfully delivered complex originator biologics for approximately 40 years, today Biogen is one of only a handful of companies with the leading manufacturing capabilities and the deep scientific expertise needed to produce biosimilars of advanced biologics. 

As many biologics reach the end of their patent lives, Biogen believes biosimilars are central to safeguarding future healthcare innovation. Biosimilars can alleviate some of the burden on healthcare systems by offering cost savings and promoting sustainable access to therapies. Biosimilars can also expand options for patients and physicians to meet individual needs. Biogen has the expertise to manufacture and reliably supply biosimilars. 

To learn about biosimilar product availability in countries in the EU, please contact your healthcare provider or visit your local Biogen affiliate website.

 

New Resources for Healthcare Professionals

At Biogen, our goal is to provide healthcare professionals with the information needed to support their clinical practice. Three new sites have been created for healthcare professionals based in the EU. They outline important information on our products, key clinical data, supporting materials and other valuable resources. 

Visit the Benepali site

Visit the Imraldi site 

Visit the Flixabi site

 

Biosimilars Medical Academy

Biogen currently serves over 200,000 patients affected by Immune Medicated Inflammatory Diseases (IMIDs) across Europe in addition to a large network of clinicians. Through our educational and digital initiatives, we aim to provide HCPs with meaningful clinical education to help them in their clinical practice. The Biosimilars Medical Academy (BMA) website has been developed with internationally renowned Key International Medical Experts (KMEs) and features key medical topics. If you are an HCP outside of the United States, please follow this link to access our website.